ENLV

Enlivex Ltd.

Nasdaq · Pharmaceutical Preparations · Inc. L3 · CIK 0001596812
$0.6687 -3.51% $167.0M
Vol
Market Cap$167.0M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (86%)
Reddit Sentiment75° Bullish
SEC Reports5
Press Releases3
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. L3·CIK 0001596812·Prev Close $0.6930

Price Targets

$20.00 +2890.9% upside Strong Buy
Current $0.6687 Low $20.00 Median $20.00 High $20.00 1 analysts
$20.00 $20.00

Analyst Ratings

Strong Buy86% buy · 7 analysts
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
Apr 7, 2026 HC Wainwright & Co. MAINTAIN Buy → Buy
Jan 12, 2026 HC Wainwright & Co. MAINTAIN Buy → Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.01 ▲ +92.3% $-0.01 — $-0.01 93% YoY 1
Next Q $-0.01 ▲ +92.9% $-0.01 — $-0.01 88% YoY 1
Current FY $-0.05 ▲ +84.4% $-0.05 — $-0.05 77% YoY 1
Next FY $-0.09 ▲ +88.5% $-0.09 — $-0.09 -13% YoY 1

Reddit Sentiment

75°
Bullish
Bearish Neutral Bullish
4 mentions 4 bullish 0 bearish

No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

Current analyst consensus: Strong Buy (86% buy). Based on 7 analysts: 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$20.00 mean target +2890.9% upside Strong Buy (3.00)
$20.00 Low $20.00 High
MetricValue
Current Price$0.6687
Target Low$20.00
Target Mean$20.00
Target Median$20.00
Target High$20.00
# Analysts1
RecommendationStrong Buy (3.00)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-03-31
$-0.01 $-0.01 $-0.01 93.3% +92.3% 1↑ 0↓ $0.0B 0.0% 1
Next Q
2026-06-30
$-0.01 $-0.01 $-0.01 87.5% +92.9% 1↑ 0↓ $0.0B 0.0% 1
Current FY
2026-12-31
$-0.05 $-0.05 $-0.05 77.2% +84.4% $0.0B 0.0% 1
Next FY
2027-12-31
$-0.09 $-0.09 $-0.09 -12.5% +88.5% $0.0B 0.0% 1

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.010
7d ago$-0.130+0.120
30d ago$-0.130+0.120
60d ago$-0.130+0.120
90d ago$-0.130+0.120
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Apr 7, 2026 HC Wainwright & Co. MAINTAIN Buy Buy
Jan 12, 2026 HC Wainwright & Co. MAINTAIN Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20262410086%
May 1, 20262410086%
Apr 1, 20262420075%
Mar 1, 20262420075%
Feb 1, 20262420075%
Jan 1, 20262420075%
Strong BuyBuyHoldSellStrong Sell

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

75°
Bullish
Bearish Neutral Bullish
4 mentions 4 bullish 0 bearish 4 time periods

Reddit Sentiment History

DateMentionsSentimentBullishBearishThreads
Jun 2, 2026160° Warm101
Jun 2, 2026160° Warm101
May 28, 2026160° Warm101
May 28, 2026160° Warm101

Recent Reddit Threads

May 25, 2026
earnings_calendar
ENLV Q1 2026 Earnings Scheduled — 2026-05-25
Apr 30, 2026
announcement
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange
<p align="center"><i>The listing on one of the world’s largest global cryptocurrency exchanges expands market access and secondary liquidity for Enliv
Apr 28, 2026
announcement
Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million
<p align="center"><i>New acquisitions from Rain Foundation underlines Enlivex’s disciplined prediction markets treasury strategy</i></p>
Apr 21, 2026
announcement
Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
<p>·      Approval by the Danish Medicines Agency (DKMA) for enrolling patients in Denmark follows the recently announced FDA clearance to initiate th
Apr 8, 2026
short_volume
Short Volume: ENLV — 63.1% short (0.6M / 0.9M)
Short: 580,859 | Exempt: 0 | TRF Vol: 920,903 | Short Ratio: 63.1% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
earnings_calendar
ENLV Q4 2025 Earnings Scheduled — 2026-03-30
Mar 24, 2026
buyback
Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program
<p align="justify">Nes-Ziona, Israel, March 24, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), a quality longevit